Xin Lang Cai Jing·2026-02-15 11:49Group 1 - The law firm Shanghai Jiucheng has successfully filed a lawsuit for investor claims against Yingfeituo (002528), with the Shenzhen Intermediate People's Court accepting the case [1] - Investors who purchased Yingfeituo stock between April 30, 2020, and April 30, 2024, and sold or continued to hold the stock after April 30, 2024, are eligible to initiate claims [2] - The China Securities Regulatory Commission (CSRC) has initiated a case against Yingfeituo for suspected violations of information disclosure laws [1] Group 2 - The law firm has also achieved a favorable ruling in a claim case for Ningke Biological (600165), with some investors already receiving compensation [2] - Ningke Biological's 2022 annual report was found to contain false records, inflating revenue by 76.5941 million and profit by 77.2220 million, which accounted for 11.25% and 46.59% of total revenue and profit, respectively [2] - Investors who bought Ningke Biological stock between November 22, 2022, and April 6, 2023, or between April 28, 2024, and October 31, 2024, are also eligible to file claims [3]